Drugs / CVX-096
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00886821 | Oct 2008 → Jun 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVX-096 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00886821 ↗ |
| Route | Subcutaneous | “Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg” NCT00886821 ↗ |